Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methodological Appraisal of Phase 3 Clinical Trials in Geographic Atrophy.
Biarnés M, Garrell-Salat X, Gómez-Benlloch A, Guarro M, Londoño G, López E, Ruiz S, Vázquez M, Sararols L. Biarnés M, et al. Among authors: sararols l. Biomedicines. 2023 May 26;11(6):1548. doi: 10.3390/biomedicines11061548. Biomedicines. 2023. PMID: 37371644 Free PMC article.
Optical Coherence Tomography in Inherited Macular Dystrophies: A Review.
Gómez-Benlloch A, Garrell-Salat X, Cobos E, López E, Esteve-Garcia A, Ruiz S, Vázquez M, Sararols L, Biarnés M. Gómez-Benlloch A, et al. Among authors: sararols l. Diagnostics (Basel). 2024 Apr 24;14(9):878. doi: 10.3390/diagnostics14090878. Diagnostics (Basel). 2024. PMID: 38732293 Free PMC article. Review.
Three-year outcomes of vascular endothelial growth factor inhibitors in naïve branch retinal vein occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Ophthalmol Retina. 2024 Apr 17:S2468-6530(24)00189-1. doi: 10.1016/j.oret.2024.04.014. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38641007
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.
Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M; Fight Retinal Blindness! Study Group. Mehta H, et al. Ophthalmol Retina. 2024 Apr 16:S2468-6530(24)00182-9. doi: 10.1016/j.oret.2024.04.008. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38615818 Free article.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Re: Heath Jeffery et al.: Analysis of the outer retinal bands in ABCA4-associated and PRPH2-associated retinopathy using OCT (Opthalmol Retina. 2023 May 18;S2468-6530(23)00209-9. doi: 10.1016/j.oret.2023.05.010. Online ahead of print.).
Biarnés M, Gómez-Benlloch A, Garrell-Salat X, Sararols L. Biarnés M, et al. Among authors: sararols l. Ophthalmol Retina. 2023 Dec;7(12):e19-e20. doi: 10.1016/j.oret.2023.07.027. Epub 2023 Aug 28. Ophthalmol Retina. 2023. PMID: 37642630 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database.
Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Moll-Udina A, Bernal-Morales C, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mosinska A, Casaroli Marano RP, Zarranz-Ventura J; from the FRB SPAIN-IMAGE Project Investigators. Martin-Pinardel R, et al. Among authors: sararols l. Br J Ophthalmol. 2024 Jan 29;108(2):253-262. doi: 10.1136/bjo-2022-322297. Br J Ophthalmol. 2024. PMID: 36627173
Guidance on brolucizumab management recommendations.
Fonollosa A, Gallego-Pinazo R, Sararols L, Adán A, López-Gálvez M, Figueroa MS. Fonollosa A, et al. Among authors: sararols l. Arch Soc Esp Oftalmol (Engl Ed). 2022 Jul 23:S2173-5794(22)00084-6. doi: 10.1016/j.oftale.2022.05.006. Online ahead of print. Arch Soc Esp Oftalmol (Engl Ed). 2022. PMID: 35882576 Free article.
34 results